ArticleArchives of toxicology2025
The deglycosylated metabolite of 2,3,5,4'-tetrahydroxystilbene-2-O-β-D- glucoside contributes to immune-mediated hepatotoxicity induced by Polygonum multiflorum.
Article in Archives of toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hepatotoxic Compounds and Mechanisms of Polygonum Multiflorum: A Narrative Review of Recent Advances.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Polygonum multiflorum (PM) has been reported to cause immune-mediated idiosyncratic liver injury. 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside (THSG) has been identified as a hepatotoxic constituent responsible for PM-induced hepatotoxicity. Covalent protein modification by reactive metabolites plays a crucial role in herb and drug-induced liver injury. Whether it is essential for the hepatotoxicity of THSG needs further clarification. THSG can be hydrolyzed into its aglycone 2,3,5,4'-tetrahydroxystilbene (THS). This study aims to investigate the impact of THS on liver injury and elucidate its underlying mechanism. Metabolism of THSG and covalent modification of cysteine residues by THS were identified by mass spectrometry and proteomics. Hepatotoxicity and T-cell immune response induced by THS were evaluated in vitro and in vivo. The immunological mechanism was investigated using PBMC from healthy donors. THS was detected in both the liver and blood samples after oral administration of THSG to mice. Cysteine-based covalent modification of glutathione (GSH), glutathione S-transferase Pi (GSTP) and hepatic proteins by THS was identified. Liver injury accompanied by inflammatory cell infiltration and T-cell activation were observed in vivo and in vitro with THS treatment. PBMCs from healthy donors and drug-specific T-cell clones (TCCs) could be activated by THS possibly through the hapten pathway. THS, the deglycosylated metabolite of THSG, functions as a hapten by covalently binding to proteins to induce cellular stress and activate T-cells, which may contribute to PM-induced hepatotoxicity.
Indexed as
Identifiers
40892063What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.